GlassScriptPhysician profile
Jill Cryder
NPI 1437682739
$7,650.21
in general payments reported to CMS, 2019-2025
23 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,615 · 2022: $1,676 · 2023: $1,720 · 2024: $1,223 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,201.19 |
| Education | $158.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,963.76 | 2021-2025 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $1,381.80 | 2021-2025 | |
| Janssen Biotech, INC. | $1,308.42 | 2021-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $755.39 | 2021-2025 | Orencia |
| Ucb, INC. | $516.02 | 2021-2025 | Cimzia, Bimzelx |
| Lilly USA, LLC | $291.40 | 2021-2023 | Taltz |
| Novartis Pharmaceuticals Corporation | $289.70 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $274.55 | 2021-2023 | Ofev, Cyltezo |
| Alexion Pharmaceuticals, INC. | $142.63 | 2023-2025 | Strensiq |
| Horizon Therapeutics Plc | $105.40 | 2021-2023 | Krystexxa |
| Fresenius Kabi USA, LLC | $100.31 | 2023 | Idacio |
| Astrazeneca Pharmaceuticals LP | $83.95 | 2022-2023 | Evusheld |
| Tersera Therapeutics LLC | $66.21 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $63.05 | 2021-2024 | Crysvita |
| Glaxosmithkline, LLC. | $57.98 | 2021-2025 | Benlysta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $51.36 | 2024-2025 | Actemra, Gazyva |
| Actelion Pharmaceuticals US, INC. | $41.98 | 2023 | Opsumit |
| Kyowa Kirin, INC. | $37.29 | 2025 | |
| Antares Pharma, INC. | $30.51 | 2021 | |
| Organon LLC | $29.59 | 2025 | |
| Sandoz INC. | $23.22 | 2023 | Hyrimoz |
| Celltrion USA INC. | $19.45 | 2023 | Yuflyma |
| Genzyme Corporation | $16.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Cryder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.